• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily.对于所有 ASCT 后复发的 HL 患者，是否都应考虑进行同种异体 SCT？需要咨询，但是不一定需要移植。
Blood Adv. 2018 Apr 10;2(7):821-824. doi: 10.1182/bloodadvances.2017011130.
2
Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?自体造血干细胞移植（SCT）后复发的所有霍奇金淋巴瘤患者是否都应考虑异体 SCT？
Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122.
3
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.在 ABVD 治疗时代，霍奇金淋巴瘤（HL）患者接受大剂量自体干细胞移植（HD-ASCT）后晚期复发。
Biol Blood Marrow Transplant. 2012 Apr;18(4):640-7. doi: 10.1016/j.bbmt.2011.08.012. Epub 2011 Aug 24.
4
Stem cell transplantation in Hodgkin lymphoma.霍奇金淋巴瘤中的干细胞移植
Hematol Oncol Clin North Am. 2014 Dec;28(6):1097-112. doi: 10.1016/j.hoc.2014.08.011. Epub 2014 Sep 26.
5
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.复发/难治性霍奇金淋巴瘤的挽救治疗：同种异体移植、维布妥昔单抗及新型药物的作用
Expert Opin Biol Ther. 2016;16(3):347-64. doi: 10.1517/14712598.2015.1130821. Epub 2016 Feb 6.
6
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.接受检查点抑制剂治疗后复发/难治性霍奇金淋巴瘤患者接受自体造血干细胞移植的潜在生存获益：真实世界经验。
Hematol Oncol. 2020 Dec;38(5):737-741. doi: 10.1002/hon.2803. Epub 2020 Sep 30.
7
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.移植前（18）F-氟脱氧葡萄糖-正电子发射断层扫描对霍奇金淋巴瘤T细胞去除异基因移植后生存结果的影响
Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.
8
Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).《意大利普利亚血液学网络（REP）回顾性多中心研究：减低强度预处理异基因造血干细胞移植治疗霍奇金淋巴瘤的结果》。
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):35-40. doi: 10.1016/j.clml.2018.08.012. Epub 2018 Sep 12.
9
Therapy of relapsed Hodgkin lymphoma.复发性霍奇金淋巴瘤的治疗
Blood Rev. 2007 Sep;21(5):233-43. doi: 10.1016/j.blre.2007.06.001. Epub 2007 Aug 1.
10
Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.异基因造血干细胞移植治疗复发难治性霍奇金淋巴瘤：单中心真实世界经验。
Pathol Oncol Res. 2021 Jul 27;27:1609867. doi: 10.3389/pore.2021.1609867. eCollection 2021.

引用本文的文献

1
Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.经典型霍奇金淋巴瘤：从过去到未来——发病机制和治疗进展的综合综述。
Int J Mol Sci. 2023 Jun 13;24(12):10095. doi: 10.3390/ijms241210095.
2
Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.重新评估异基因造血干细胞移植在复发难治性霍奇金淋巴瘤中的作用：近期进展与结果
J Pers Med. 2022 Jan 18;12(2):125. doi: 10.3390/jpm12020125.
3
The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.异基因干细胞移植前实现完全缓解对霍奇金淋巴瘤无进展生存期的影响。
Clin Hematol Int. 2021 Jul 15;3(3):116-118. doi: 10.2991/chi.k.210704.002. eCollection 2021 Sep.
4
Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.异基因造血干细胞移植治疗复发难治性霍奇金淋巴瘤：单中心真实世界经验。
Pathol Oncol Res. 2021 Jul 27;27:1609867. doi: 10.3389/pore.2021.1609867. eCollection 2021.
5
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.自体移植失败后，采用TLI-ATG预处理的异基因移植治疗霍奇金淋巴瘤。
Blood Adv. 2018 Jul 10;2(13):1547-1550. doi: 10.1182/bloodadvances.2018021071.

本文引用的文献

1
Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma.自体造血细胞移植后巩固性放射治疗在复发性或难治性霍奇金淋巴瘤治疗中的作用
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):94-102. doi: 10.1016/j.ijrobp.2017.05.007. Epub 2017 May 15.
2
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.异基因造血细胞移植后复发淋巴瘤的程序性死亡受体-1阻断治疗：缓解率高但移植物抗宿主病频繁。
Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.
3
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.帕博利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤的疗效和安全性II期研究。
J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.
4
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.含加速全身淋巴照射的挽救方案治疗难治性和复发性霍奇金淋巴瘤患者：20年经验
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1066-1076. doi: 10.1016/j.ijrobp.2017.01.222. Epub 2017 Feb 1.
5
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.早期正电子发射断层扫描反应适应性治疗 I 期和 II 期霍奇金淋巴瘤：随机 EORTC/LYSA/FIL H10 试验的最终结果。
J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.
6
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.异基因造血干细胞移植后纳武利尤单抗治疗复发霍奇金淋巴瘤的疗效和耐受性。
Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7.
7
Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?自体移植后霍奇金淋巴瘤复发：是时候重新思考治疗方法了吗？
Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):47-56. doi: 10.1016/j.hemonc.2016.12.002. Epub 2017 Feb 1.
8
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.复发/难治性淋巴瘤患者接受PD-1阻断治疗后进行异基因造血干细胞移植的安全性和有效性
Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10.
9
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.近年来复发/难治性霍奇金淋巴瘤的清髓性与减低强度异基因造血干细胞移植：欧洲血液和骨髓移植学会淋巴瘤工作组的回顾性分析。
Ann Oncol. 2016 Dec;27(12):2251-2257. doi: 10.1093/annonc/mdw421. Epub 2016 Oct 24.
10
Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.复发难治性霍奇金淋巴瘤且符合移植条件患者的新型药物及策略
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):331-338. doi: 10.1182/asheducation-2016.1.331.

对于所有 ASCT 后复发的 HL 患者，是否都应考虑进行同种异体 SCT？需要咨询，但是不一定需要移植。

Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily.

机构信息

Division of Hematologic Oncology, Lymphoma Service, and Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and Department of Medicine, Weill Cornell Medical College, New York, NY.

出版信息

Blood Adv. 2018 Apr 10;2(7):821-824. doi: 10.1182/bloodadvances.2017011130.

DOI:10.1182/bloodadvances.2017011130
PMID:29636328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5894256/
Abstract

This article has a companion Point by Peggs.

摘要

本文有佩格斯的相关观点。